Answers are grounded in this paper and cite their sources.
Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as well as in future trials to target specific subgroups of patients.
No takes yet. Share an insight, caveat, or question.
León‐Castillo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: